ATE345819T1 - Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung - Google Patents

Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung

Info

Publication number
ATE345819T1
ATE345819T1 AT00966810T AT00966810T ATE345819T1 AT E345819 T1 ATE345819 T1 AT E345819T1 AT 00966810 T AT00966810 T AT 00966810T AT 00966810 T AT00966810 T AT 00966810T AT E345819 T1 ATE345819 T1 AT E345819T1
Authority
AT
Austria
Prior art keywords
capsid
recombinant adenovirus
modified recombinant
adenoviral vector
targeted
Prior art date
Application number
AT00966810T
Other languages
English (en)
Inventor
David T Curiel
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Application granted granted Critical
Publication of ATE345819T1 publication Critical patent/ATE345819T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00966810T 1999-09-24 2000-09-22 Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung ATE345819T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15610499P 1999-09-24 1999-09-24

Publications (1)

Publication Number Publication Date
ATE345819T1 true ATE345819T1 (de) 2006-12-15

Family

ID=22558110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966810T ATE345819T1 (de) 1999-09-24 2000-09-22 Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung

Country Status (8)

Country Link
US (2) US6555368B1 (de)
EP (1) EP1214098B1 (de)
JP (1) JP2003509079A (de)
AT (1) ATE345819T1 (de)
AU (1) AU773019B2 (de)
CA (1) CA2384827A1 (de)
DE (1) DE60031994T2 (de)
WO (1) WO2001021216A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214098B1 (de) * 1999-09-24 2006-11-22 The Uab Research Foundation Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
AU2001234981A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
EP1390476A4 (de) * 2001-04-17 2005-03-30 Vectorlogics Inc Mosaik-adenovirusvektoren
AU2002344190B2 (en) * 2001-05-30 2007-10-18 Transgene S.A. Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
CA2490866A1 (en) * 2002-06-26 2004-01-08 Advanced Bionutrition Corporation Viruses and virus-like particles for multiple antigen and target display
EP1631582A2 (de) * 2003-06-10 2006-03-08 University of Saskatchewan Chimäre adenoviruscapsidproteine
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
WO2006119449A2 (en) * 2005-05-04 2006-11-09 Vectorlogics, Inc. Modified adenovirus containing a stabilized antibody
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
EP3132038A4 (de) 2014-04-18 2017-11-29 Washington University Adenovirales targeting, zusammensetzungen und verfahren dafür
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (de) 2016-12-12 2020-08-26 Salk Institute for Biological Studies Auf tumoren gerichtete synthetische adenoviren und verwendungen davon
KR20190098215A (ko) 2016-12-21 2019-08-21 멤젠 엘엘씨 무장된 복제-가능 종양 분해 아데노바이러스
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333115D1 (de) 1992-09-22 2003-08-28 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5962311A (en) * 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
JP2001520511A (ja) 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
WO1999036545A2 (en) * 1998-01-16 1999-07-22 Genzyme Corporation Adenoviral vectors with modified capsid proteins
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
EP1214098B1 (de) * 1999-09-24 2006-11-22 The Uab Research Foundation Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
AU2001234981A1 (en) * 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix

Also Published As

Publication number Publication date
US6555368B1 (en) 2003-04-29
EP1214098A1 (de) 2002-06-19
AU773019B2 (en) 2004-05-13
DE60031994T2 (de) 2007-09-20
EP1214098A4 (de) 2002-10-30
US20030175244A1 (en) 2003-09-18
DE60031994D1 (de) 2007-01-04
AU7709800A (en) 2001-04-24
JP2003509079A (ja) 2003-03-11
EP1214098B1 (de) 2006-11-22
WO2001021216A1 (en) 2001-03-29
CA2384827A1 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE345819T1 (de) Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
ATE288496T1 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
NO20025402D0 (no) Modifiserte ES-celler og ES-spesifikt gen
ZA200110161B (en) Anti-avB3 recombinant human antibodies, nucleic acids encoding same and methods of use.
EP0757717A4 (de) Papillomavirus vakzine
AU3438900A (en) Use of trehalose for stabilising a liquid vaccine
IS4762A (is) Samfallandi eitlaveiru genaferjukerfi og frumulínur
AU4981101A (en) Subtilisin variants
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DK0976829T3 (da) Protein-deamiderende enzym, gen kodende for dette, fremgangsmåde til fremstilling heraf same anvendelse heraf
NO20020571D0 (no) Peptider som blokkerer virusinfeksjonsevnen og fremgangsmåter for anvendelse av disse
WO2000053776A3 (en) Human kallikrein-like genes
ATE280947T1 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DK1082423T3 (da) Cyclin E2-gener og -proteiner
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
DK1411128T3 (da) Rekombinante, virale vektorer indeholdende genet for den humane urogenaseplasminogenaktivator og deres anvendelse ved behandling af hepatitisk fibrose
NO971247L (no) Defektive, rekombinante adenoviruser med inaktivt IVa2-gen
EP1177207A4 (de) Für das prostataspezifische membran-antigenartige gen kodierende dna und ihre verwendung
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
WO2002042325A3 (en) Cyp1b1 nucleic acids and methods of use
NO20021634D0 (no) Fremstilling av rekombinante adenoviruser og adenovirusbanker
ES2181444T3 (es) Composicion para la induccion de una respuesta inmunologica especifica de un tumor, metodo para la produccion y utilizacion de dicha composicion en el tratamiento de neoplasias.
EP1134285A4 (de) Nukleinsäure-fragment, dieses fragment enthaltender rekombinanter vektor und dadurch vermitteltes verfahren zur unterstützung der expression eines strukturgens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties